Indatuximab ravtansine

Drug Profile

Indatuximab ravtansine

Alternative Names: Anti-myeloma monoclonal antibody-DM4 immunoconjugate BT-062; BT-062; Maytansinoid-conjugated anti-myeloma monoclonal antibody BT-062; N2'-Deacetyl-N2'-[4-Methyl-4-(Oxobuthyldithio)-1-Oxopentyl]-Maytansine-Chimerized Anti-Cd138 Igg4 Monoclonal Antibody; nBT062

Latest Information Update: 09 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biotest
  • Developer Biotest AG
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Multiple myeloma
  • Phase I/II Bladder cancer; Breast cancer

Most Recent Events

  • 04 Feb 2015 Indatuximab ravtansine is still in phase I/II trials for Multiple myeloma (Monotherapy, Combination therapy, Second-line therapy or greater) in USA
  • 25 Mar 2014 Phase-I/II clinical trials in Bladder cancer (metastatic disease, monotherapy, second-line therapy or greater) in Germany (IV) (EudraCT2013-003252-20)
  • 25 Mar 2014 Phase-I/II clinical trials in Breast cancer (metastatic, monotherapy, second-line therapy or greater, triple-negative) in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top